trending Market Intelligence /marketintelligence/en/news-insights/trending/f8ZelLBivWfuhdYYQEM0zg2 content esgSubNav
In This List

Aptose Biosciences closes common stock offering

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Aptose Biosciences closes common stock offering

Aptose Biosciences Inc. raised about $21.3 million in an offering of its 10 million common shares priced at $1.85 apiece.

The shares sold include the full exercise of the underwriters' option to buy an additional 1.5 million common shares.

Net proceeds will be used to accelerate and expand Aptose's clinical trial programs, along with working capital and general corporate purposes.

RBC Capital Markets and Canaccord Genuity acted as joint book-running managers for the offering, with H.C. Wainwright & Co. and JonesTrading Institutional Services LLC as co-managers.